Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Immunomodulatory and Immunotherapeutic Properties of Recombinant γ-Interferon and Recombinant Tumor Necrosis Factor in Mice

James E. Talmadge, Henry R. Tribble, Robin W. Pennington, Hamblin Phillips and Robert H. Wiltrout
James E. Talmadge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry R. Tribble
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin W. Pennington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamblin Phillips
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Wiltrout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 1987
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

These studies were designed to examine the immunomodulatory and immunotherapeutic properties of recombinant murine interferon gamma (rM IFN-γ) and recombinant human tumor necrosis factor (rH TNF). We report that rM IFN-γ activated murine natural killer cells and macrophages in a dose-dependent manner in vivo. The rM IFN-γ, which demonstrated a bell-shaped therapeutic response curve, must be administered at specific doses and schedules to produce optimal therapeutic activity. Optimal activity was observed after i.v. administration of 50,000 U/animal rM IFN-γ three times per week. In contrast, rH TNF produced its major therapeutic activity in the treatment of metastatic disease after i.v. but not i.p. administration. The therapeutic effects of rH TNF were as great in these in vivo systems as those of rM IFN-γ. Furthermore, rH TNF had additive therapeutic activity when administered in conjunction with suboptimal doses of rM IFN-γ. Unlike rM IFN-γ, rH TNF did not activate natural killer cells in vivo or in vitro but did augment in vivo and in vitro macrophage tumoricidal activity. It also had synergistic cytostatic properties with rM IFN-γ for some murine tumor cell lines in vitro. High levels of rH TNF were readily detected in the serum with a half-life of approximately 30 min after i.v. administration. In contrast, only minimal serum TNF activity occurred after i.p. administration, suggesting that i.v. administration may more efficiently facilitate systemic therapeutic activity. In summary, rH TNF and rM IFN-γ have therapeutic activity for metastatic disease as individual agents and additive therapeutic activity when used in combination. Furthermore, it appears that in addition to therapeutic potential as cytostatic agents, the immunomodulatory properties of rH TNF have a role in its therapeutic properties.

Footnotes

  • ↵1 This research was sponsored by the Biological Resources Branch, Biological Response Modifiers Program, Division of Cancer Treatment of the National Cancer Institute, Department of Health and Human Services, under contract no. N01-23910 with Program Resources, Inc. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government.

  • ↵2 To whom requests for reprints should be addressed, at National Cancer Institute, Frederick Cancer Research Facility, Preclinical Screening Laboratory, P.O. Box B, Frederick, MD 21701.

  • Received June 2, 1986.
  • Revision received October 10, 1986.
  • Revision received February 6, 1987.
  • Accepted February 13, 1987.
  • ©1987 American Association for Cancer Research.
PreviousNext
Back to top
May 1987
Volume 47, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Immunomodulatory and Immunotherapeutic Properties of Recombinant γ-Interferon and Recombinant Tumor Necrosis Factor in Mice
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunomodulatory and Immunotherapeutic Properties of Recombinant γ-Interferon and Recombinant Tumor Necrosis Factor in Mice
James E. Talmadge, Henry R. Tribble, Robin W. Pennington, Hamblin Phillips and Robert H. Wiltrout
Cancer Res May 15 1987 (47) (10) 2563-2570;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunomodulatory and Immunotherapeutic Properties of Recombinant γ-Interferon and Recombinant Tumor Necrosis Factor in Mice
James E. Talmadge, Henry R. Tribble, Robin W. Pennington, Hamblin Phillips and Robert H. Wiltrout
Cancer Res May 15 1987 (47) (10) 2563-2570;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Basic Sciences

Articles

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement